Delivery Order SPE2DB22D1041-SPE2DB24FUCP3

Award Date 7/12/24
Potential Completion Date 7/15/24
Potential Value $6.9K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award from the Defense Logistics Agency (DLA) was made to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $15,840.66 Firm Fixed Price delivery order contract is for the supply of Candesartan Cilexetil 16 mg tablets. The contract has an ultimate completion date of July 5, 2024. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical which serves as a primary vehicle...
This is a federal contract award issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $10,854.92, is a delivery order for the supply of Candesartan Cilexetil 16 mg tablets. The contract has an ultimate completion date of March 21, 2025 and is a firm fixed-price contract. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical,...
This is a federal contract award from the Defense Logistics Agency (DLA) Troop Support Medical to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $12,096.72, is for the delivery of Candesartan Cilexetil 8 mg tablets. It is a firm fixed-price delivery order contract with a completion date of February 18, 2025. The award is not designated as a set-aside contract. AmerisourceBergen holds a larger $999,999,999 Indefinite...
This federal contract award, valued at $7,570.40, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of Candesartan Cilexetil 16 mg tablets, a cardiovascular medication. This is a firm fixed-price delivery order contract that will run through January 14, 2025. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support...
This federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, was issued by the Defense Logistics Agency (DLA) for the delivery of 4,566,514,819 units of Candesartan Cilexetil 32 mg tablets. The firm-fixed-price delivery order, valued at $2,264.64, has a completion date of November 22, 2024. The contract is not designated as a set-aside. Amerisourcebergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $2,765.44 firm fixed-price delivery order is for the supply of Candesartan Cilexetil 16 mg tablets with an ultimate completion date of April 29, 2025. Amerisourcebergen holds a significant $999,999,999.00 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, designated as SPE2DX, which provides a...
This is a federal contract award issued by the Defense Logistics Agency (DLA) Troop Support Medical to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,127.39 firm fixed-price delivery order is for the supply of Candesartan Cilexetil 4 mg tablets in 90-count packages. The contract has an ultimate completion date of January 14, 2025. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $6,357.54 Firm Fixed Price Delivery Order contract is for the supply of 4,567,599,451 units of Candesartan Cilexetil 8 mg tablets. The contract has an ultimate completion date of March 18, 2025. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical...
This federal contract award, with ID SPE2DB20D3101|SPE2DB25FQWR0, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The $5,474.47 firm fixed-price delivery order is for the supply of Candesartan Cilexetil 16 mg tablets. The contract has an ultimate completion date of December 11, 2024. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $7,347.24 firm fixed-price delivery order is for the supply of Candesartan Cilexetil 16 mg tablets. The contract has an ultimate completion date of February 14, 2025. Amerisourcebergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary...
  • SPE2DB22D1041
    Indefinite Delivery Contract
  • SPE2DB22D1041-SPE2DB24FUCP3
    Delivery Order

This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract has an award value of $6,917.16 and provides for the delivery of Candesartan Cilexetil 16 mg tablets. The contract does not have a set-aside designation, indicating open competition.

AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical worth $999,999,999 through November 2026. This IDC serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The company also maintains a separate IDC with the Department of Justice Federal Bureau of Investigation, valued at $750,000 through May 2024, which covers similar medical products and prescription drugs. These IDCs enable efficient government procurement of essential pharmaceutical and medical supplies, serving the healthcare needs of military personnel, veterans, and other federal beneficiaries.

Generated 5/17/25, 10:05 AM